Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 54, Issue 7, Pages 2179-2184Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201410341
Keywords
bacterial virulence; drug design; EcDsbA; fragment-based drug discovery; medicinal chemistry
Categories
Funding
- National Health and Medical Research Council [1009785]
- Australian Research Council [FL0992138, FT130100580, DE130101169]
- Australian Research Council [FT130100580, DE130101169, FL0992138] Funding Source: Australian Research Council
Ask authors/readers for more resources
The thiol-disulfide oxidoreductase enzyme DsbA catalyzes the formation of disulfide bonds in the periplasm of Gram-negative bacteria. DsbA substrates include proteins involved in bacterial virulence. In the absence of DsbA, many of these proteins do not fold correctly, which renders the bacteria avirulent. Thus DsbA is a critical mediator of virulence and inhibitors may act as antivirulence agents. Biophysical screening has been employed to identify fragments that bind to DsbA from Escherichia coli. Elaboration of one of these fragments produced compounds that inhibit DsbA activity in vitro. In cell-based assays, the compounds inhibit bacterial motility, but have no effect on growth in liquid culture, which is consistent with selective inhibition of DsbA. Crystal structures of inhibitors bound to DsbA indicate that they bind adjacent to the active site. Together, the data suggest that DsbA may be amenable to the development of novel antibacterial compounds that act by inhibiting bacterial virulence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available